Insights

Insights From Our Experts

Articles

Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders

 Launching in today’s unpredictable market is a journey with new challenges around every corner. While product pipelines are rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build…

Insight from Frontiers Health: Harnessing Machine Learning to Transform Clinical Outcomes

Our Chief Medical Officer, Dr. Pierantonio Russo, joined on stage at Frontiers Health 2024 to discuss the impact of Machine Learning (ML) on healthcare, particularly in predicting hospital readmissions and managing chronic diseases. In this session,…

The Promise of Direct-to-Patient – What’s Really Needed for Patient Access

In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with…

The Importance of Quality-of-Life Metrics in mCRPC

Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable…

White Paper: The Increasing Role of AI in Improving the Diagnostic Imaging Landscape
The Increasing Role of AI in Improving the Diagnostic Imaging Landscape

Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI…

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs

The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…

Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare

EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and…

Finding the Human Element Amid the Algorithms

The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger?  Spend more than a few minutes of…

Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways

Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by EVERSANA MANAGEMENT CONSULTING, delves into the shifting landscape of oncology…

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA

Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…